Clareo Health | Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer
T1-4N0-2, lesion size of ≥2cm, at time of the restaging FDG PET/CT
Planned to undergo resection after chemo-IO according to routine treatment guidelines
Willing and able to provide written informed consent for the trial
Above 18 years of age on day of signing informed consent
Have measurable disease based on RECIST 1.1
Have a ECOG performance status of 0-1, and are considered operable based on pulmonary function test and/or exercise testing
You may not be if
Patients deemed inoperable
Patients who have received a splenectomy
Patients who have received any vaccination within 14 days of enrollment
Patients with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid \>10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial.
